RxDoctor Payments Data

Joshua Vega, MD

Cardiovascular Disease · Raleigh, NCNPI 1790074870

Payments from drug & device makers

$2,662in general payments, 2019–2025

Across 144 payments — averaging $18.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$397
  • AstraZeneca$335
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$275
  • Boston Scientific$271
  • Novartis$199
  • Heartflow, Inc.$129
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,662100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,662 in reported general payments places this provider in the 50th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$144,654
Medicare patients
744
Services billed
1,741

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban265$257,188
EntrestoSacubitril/Valsartan82$79,321
XareltoRivaroxaban76$66,531
Repatha SureclickEvolocumab34$29,817
FarxigaDapagliflozin Propanediol31$21,626
JardianceEmpagliflozin14$17,827
MultaqDronedarone Hcl12$9,103
Ranolazine ErRanolazine38$4,319
Metoprolol Succinate226$2,665
Atorvastatin Calcium201$2,458
ClopidogrelClopidogrel Bisulfate157$1,915
Flecainide Acetate72$1,555
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine12$1,300
Amlodipine Besylate157$1,272
Carvedilol171$1,241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$397$257,188265 claims
NovartisEntresto$199$79,32182 claims
Johnson & JohnsonXarelto$15$66,53176 claims
AstraZenecaFarxiga$335$21,62631 claims
Boehringer IngelheimJardiance$31$17,82714 claims
Sanofi-aventis U.S. LLCMultaq$120$9,10312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →